LTZ Therapeutics Secures Over USD 20 Million in Series A Financing to Advance Immunotherapy Pipeline
LTZ Therapeutics Inc., a biotechnology company specializing in immunotherapy with operations in both the US...
Fineline Cube
Shanghai Sanyou Medical Gains NMPA Approval for 3D Printed Cervical Fusion Device
Shanghai Sanyou Medical Co., Ltd (SHA: 688085), a prominent player in the medical device industry...
Guangzhou Red Pine Medical Secures Series D Funding to Accelerate Global Expansion
Guangzhou Red Pine Medical Instrument Co., Ltd., a leading company in the disposable endoscope sector,...
China’s H1 2024 Pharmaceutical Trade Data Indicates Mixed Performance in Global Markets
The Ministry of Industry and Information Technology (MIIT) has released a report on the first...
China’s NHC Reports 2023 County Hospital Medical Service Capability Evaluation Results
The National Health Commission (NHC) of China has released a notice detailing the results of...
EU Regulator Rejects Marketing Authorization for Biogen and Eisai’s Alzheimer’s Drug Leqembi
Biogen Inc. (NASDAQ: BIIB), a US biotechnology company, and its Japanese counterpart Eisai Co., Ltd...
Yipinhong Pharmacy Repays $36.7 Million in Bromhexine Marketing Settlement
Yipinhong Pharmacy Co., Ltd (SHE: 300723), a China-based pharmaceutical company, has made a significant repayment...
Luye Pharma’s Antipsychotic Erzofri Gains FDA Nod for Schizophrenia Treatment
Luye Pharma Group (HKG: 2186), a leading pharmaceutical company based in China, has achieved a...
AstraZeneca Charts Comprehensive Anti-Obesity Strategy with GLP-1 and Amylin Therapies
AstraZeneca (AZ; NASDAQ: AZN), a UK-based pharmaceutical giant, has outlined its strategic advancements and future...
Bristol-Myers Squibb Q2 2024 Sales Boosted by Growth Portfolio, Offset by R&D Impairment
Bristol-Myers Squibb (BMS; NYSE: BMY) has announced its financial results for the second quarter of...
3SBio’s Thrombopoietin Meets Primary Endpoint in Phase III Trial for Chronic Liver Disease Patients
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, has announced the successful conclusion...
CStone Pharmaceuticals’ Sugemalimab Wins EU Nod as First-Line NSCLC Treatment
CStone Pharmaceuticals (HKG: 2616), a leading biopharmaceutical company based in China, has received marketing approval...
Alphamab’s KN057 Earns FDA Orphan Drug Designation for Hemophilia B Treatment
Alphamab Oncology (HKG: 9966), a biopharmaceutical company based in China, has received another orphan drug...
Junshi Biosciences’ Toripalimab Recommended for EU Approval for Two Indications
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180) has been recommended for approval by...
Akeso Biopharma’s Ivonescimab NDA Accepted by NMPA, Strengthening NSCLC Treatment Options
Akeso Biopharma (HKG: 9926), a biopharmaceutical company based in China, has received a significant boost...
Beijing Balance Medical Secures NMPA Nod for Pioneering Heart Valve Patch
Beijing Balance Medical Technology Co., Ltd (SHA: 688198), a leading medical technology firm based in...
Hengrui Pharmaceuticals Advances in Breast Cancer Treatment with NMPA Clinical Trial Greenlight
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a pharmaceutical heavyweight based in China, has received...
MicroPort MedTech’s Aortic Occlusion Catheter Gets Green Light from China’s NMPA
Shanghai MicroPort Endovascular MedTech Co., Ltd (SHA: 688016), a leading player in the medical technology...
Zhejiang Haichang Biotech Secures EU Approval for Apexelsin: A New Hope in Cancer Treatment
Zhejiang Haichang Biotech Co., Ltd, a partner of China-based Kexing Pharmaceutical (SHA: 688136), has secured...
China Unveils Comprehensive 2030 Plan to Combat Diabetes
China’s National Health Commission (NHC), in collaboration with 12 other ministries, has unveiled the ‘Health...